2-isopropyl-3-methoxy-propan-1-ol | 785803-82-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-isopropyl-3-methoxy-propan-1-ol
• 英文别名: 2-(Methoxymethyl)-3-methylbutan-1-ol；2-(methoxymethyl)-3-methylbutan-1-ol
• CAS: 785803-82-9
• 化学式: C₇H₁₆O₂
• 分子量: 132.203
• InChiKey: DLZSAVFSIWBIPU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-isopropyl-3-methoxy-propan-1-ol 在 dirhodium tetraacetate 、 甲酸 、 氯磺酰异氰酸酯 、 碘苯二乙酸 、 magnesium oxide 作用下， 以 二氯甲烷 、 N,N-二甲基乙酰胺 、 乙腈 为溶剂， 反应 1.0h， 生成 4,4-dimethyl-5-(methoxymethyl)tetrahydro-1,2,3-oxathiazine-2,2-dioxide
  参考文献：
  名称：

  Rh催化的醚化Calpha-H键胺化：合成复杂胺类的通用策略。

  摘要：

  DOI：

  10.1002/anie.200460791
• 作为产物：
  描述：

  2-methoxymethyl-3-methyl-butyric acid 在 乙醚 、 硫酸 、 sodium acetate 作用下， 生成 2-isopropyl-3-methoxy-propan-1-ol
  参考文献：
  名称：

  Gol'mow; Afanas'ew, Zhurnal Obshchei Khimii, 1952, vol. 22, p. 1953,1956; engl. Ausg. S. 2001, 2004

  摘要：

  DOI：

文献信息

• HETEROCYCLE AND CARBOCYCLE DERIVATIVES HAVING TRKA INHIBITORY ACTIVITY
  申请人：Shionogi & Co., Ltd.

  公开号：US20170240512A1

  公开（公告）日：2017-08-24

  The present invention relates to a compound represented by Formula (I): wherein -L- is —C(═X)—, or the like, —Z— is —NR 5 —, or the like, —Z A — is —NR 5A —, or the like, —W— is —C(R 8 R 9 )n-, —W A — is —C(R 3 R 4 )m-, B is substituted or unsubstituted aromatic carbocyclyl, or the like, Y is a bond, or the like, the ring C is a substituted or unsubstituted aromatic heterocycle, or the like, R 2 is a hydrogen atom, or the like, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising thereof.

  本发明涉及一种由式（I）表示的化合物：其中-L-为—C(═X)—，或类似的，—Z—为—NR5—，或类似的，—ZA—为—NR5A—，或类似的，—W—为—C(R8R9)n-，—WA—为—C(R3R4)m-，B为取代或未取代的芳香环烃基，或类似的，Y为键，或类似的，环C为取代或未取代的芳香杂环，或类似的，R2为氢原子，或类似的，或其药学上可接受的盐，或包括其的药物组成。
• PYRROLIDINYL UREA, PYRROLIDINYL THIOUREA AND PYRROLIDINYL GUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS
  申请人：Allen Shelley

  公开号：US20150166564A1

  公开（公告）日：2015-06-18

  Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R 1 , R 2 , R a , R b , R c , R d , X, Y, B, and Ring C are as defined herein, and wherein the Y—B moiety and the NH—C(═X)—NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.

  化合物I的公式：或其立体异构体、互变异构体、药学上可接受的盐、溶剂或前药，其中R1、R2、Ra、Rb、Rc、Rd、X、Y、B和环C的定义如本文所述，其中Y-B基团和NH-C（═X）-NH基团处于反式构象，是TrkA激酶的抑制剂，可用于治疗可以通过TrkA激酶抑制剂治疗的疾病，例如疼痛、癌症、炎症、神经退行性疾病和某些传染病。
• A mechanistic analysis of the Rh-catalyzed intramolecular C–H amination reaction
  作者：Kristin Williams Fiori、Christine G. Espino、Benjamin H. Brodsky、J. Du Bois

  DOI：10.1016/j.tet.2008.11.073

  日期：2009.4

  A detailed mechanistic investigation of the intramolecular dirhodium tetracarboxylate-catalyzed sulfamate ester C-H amination reaction is presented. These studies provide support for the formation of a sulfamate-derived iminoiodinane, which reacts rapidly with the rhodium catalyst to generate a nitrenoid-type oxidant. Reactivity patterns, Hammett analysis, kinetic isotope measurement, and a cyclopropane clock experiment are indicative of a concerted, asynchronous transition structure in the product-determining C-H insertion event. (C) 2008 Published by Elsevier Ltd.
• PYRROLIDINYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS
  申请人：ARRAY BIOPHARMA INC.

  公开号：US20160297758A1

  公开（公告）日：2016-10-13

  Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R 1 , R 2 , R a , R b , R c , R d , X, Ring B, and Ring C are as defined herein, and wherein Ring B moiety and the NH—C(═X)—NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.
• PYRROLIDINYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS
  申请人：ARRAY BIOPHARMA INC.

  公开号：US20160297796A1

  公开（公告）日：2016-10-13

  Compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R 1 , R 2 , R a , R b , R c , R d , X, Ring B, and Ring C are as defined herein, and wherein Ring B moiety and the NH—C(═X)—NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.